Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 15

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 15
---
ANCING ACTIVITIES:                                                 |     |            |             |   |     |              |            |   |     |              |           |   |
| Issuance of common shares to Keystone Capital LLC for equity line of credit    |     | $          |           - |   |     | $            |    250,000 |   |     | $            |         - |   |
| Issuance of common shares to Arena Investors LP for equity line of credit      |     | $          |           - |   |     | $            |    500,000 |   |     | $            |         - |   |
| Conversion of Series A, Series B and Series C Preferred Stock to common stock  |     | $          |   2,074,340 |   |     | $            |          - |   |     | $            |         - |   |
| Reclassification of deferred offering costs to additional paid-in capital      |     | $          |     112,232 |   |     | $            |          - |   |     | $            |         - |   |
| Reclassification of accrued expenses to accounts payable                       |     | $          |   1,143,826 |   |     | $            |          - |   |     | $            |         - |   |
| Issuance of Series D preferred stock for investment in equity securities       |     | $          |     500,000 |   |     | $            |          - |   |     | $            |         - |   |

<div align='center'>See accompanying notes to the condensed consolidated financial statements

5

CERO THERAPEUTICS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2025

(Unaudited)</div>

NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Nature of Operations –CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) (“CERo”, “Successor” or the “Company”), F/K/A Phoenix Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021. PBAX was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (a “business combination”).

The Company is an innovative immunotherapy company